Oscar Tahuahua/X
Jul 14, 2025, 10:07
Oscar Tahuahua: Emotional Distress and Response to TIL Therapy In Phase III Melanoma Trial
Oscar Tahuahua, Medical Oncology Fellow at National Cancer Institute(Mexico), shared a post on X:
“Post-hoc Ph3 trial Pretreatment Emotional Distress in adv. Melanoma was linked to lower ORR with TIL Tx (37% vs 69%) & 2y PFS (16% vs 35%). A modifiable factor that may reduce immunotherapy efficacy, underscoring the stress-immune-cancer axis.”
Read the full article here.
More about Immunotherapy for Melanoma on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 14, 2025, 11:10
Jul 14, 2025, 08:10
Jul 14, 2025, 07:53
Jul 14, 2025, 03:39